Q-omics provides the consensus-scored MIR4804 profile across patient tissues and cancer cell-line models. MIR4804 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR4804 is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, MIR4804 RNA expression shows 7,822 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight LUAD, HNSC, and COAD as cancer lineages where MIR4804 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4804 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4804 survival associations across molecular data types. MIR4804 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4804 RNA expression–survival associations across cancer types. High MIR4804 expression shows unfavorable associations in LUAD, LUSC, THCA, SARC, ESCA and KICH. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR4804 RNA expression.
This table summarizes MIR4804 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4804. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4804 shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher MIR4804 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p = .022).
This table shows molecular features associated with MIR4804 in patient tissues and cancer cell lines. In patient samples, MIR4804 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
